BL Pharmtech Balance Sheet Health
Financial Health criteria checks 6/6
BL Pharmtech has a total shareholder equity of ₩31.8B and total debt of ₩3.8B, which brings its debt-to-equity ratio to 11.8%. Its total assets and total liabilities are ₩44.8B and ₩13.0B respectively.
Key information
11.8%
Debt to equity ratio
₩3.75b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩13.21b |
| Equity | ₩31.80b |
| Total liabilities | ₩13.00b |
| Total assets | ₩44.80b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A065170's short term assets (₩16.9B) exceed its short term liabilities (₩8.0B).
Long Term Liabilities: A065170's short term assets (₩16.9B) exceed its long term liabilities (₩5.0B).
Debt to Equity History and Analysis
Debt Level: A065170 has more cash than its total debt.
Reducing Debt: A065170's debt to equity ratio has reduced from 30.1% to 11.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A065170 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A065170 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 12.8% per year.